



Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: www.ajicjournal.org

Letter to the Editor

Microbicidal actives with virucidal efficacy against SARS-CoV-2

To the Editor,

Given the practical importance of microbicides having efficacy against SARS-CoV-2 in home, community, and health care settings, we report evidence of the virucidal efficacy of a number of formulated microbicidal actives against SARS-CoV-2, as evaluated per ASTM International^{1,2} and EN³ standards.

Dissemination of SARS-CoV-2 from infected to susceptible individuals is believed to occur directly, via respiratory droplets and droplet nuclei/aerosols, and indirectly through contaminated high-touch environmental surfaces (HITES).⁴ SARS-CoV-2 has been reported to remain infectious on contaminated HITES for hours to days,⁵ allowing for onward self-infection of new individuals when contaminated hands come into contact with susceptible tissues (mucous membranes of the nose, eyes, and mouth). This *Droplets-HITES-Hands* nexus⁵ is central to the chain of infection with SARS-CoV-2, and highlights the critical role that targeted application of effective microbicides against potentially contaminated HITES and hands plays in infection prevention and control during the ongoing COVID-19 pandemic.

Fortunately, enveloped viruses such as SARS-CoV-2 are among the most susceptible of pathogens to formulated microbicidal actives and detergents (including personal care soaps and liquid hand washes).^{7,8} Inactivation of such viruses by formulated microbicidal actives and detergents is believed to occur as a result of disruption of the virally modified, host-cell-derived, phospholipid bilayer glycoproteinaceous envelope, and the associated spike glycoproteins that interact with the angiotensin-converting enzyme receptor required for infection of host cells.⁸

Virucidal efficacy of a selection of formulated microbicidal actives against SARS-CoV-2 has, to date, been assumed based on efficacy data obtained using other coronaviruses^{8,9} or, as reported recently,⁵ based on nonstandardized methods of assessing viral inactivation (ie, log₁₀ reduction in infectious titer) in suspension without details of the testing method used including appropriate controls. To date, virucidal activity against SARS-CoV-2 has not been demonstrated definitively through testing conducted per standardized surface² and suspension^{1,3} methodologies. In Table 1, we provide definitive evidence of efficacy for inactivation of SARS-CoV-2, on contaminated prototypic HITES and suspensions, of products formulated with the following microbicidal actives: ethyl alcohol, para-chloro-meta-xyleneol, salicylic acid, and quaternary ammonium compounds. All of the microbicidal actives were effective for inactivating SARS-CoV-2, demonstrating ≥ 3.0 to ≥ 4.7 log₁₀ reduction of infectious virus within the tested 1 to 5 minutes contact time in virucidal efficacy testing conducted per applicable ASTM International and EN standards.

To our knowledge, this is the first report of the virucidal efficacy of formulated microbicidal actives, determined using industry/regulatory-

Table 1
Virucidal efficacy of formulated microbicidal actives against SARS-CoV-2*

Product type	Active ingredient concentration		Temperature (°C)	Contact time (minutes)	Log ₁₀ reduction in infectious SARS-CoV-2 titer achieved
	In product	Tested			
Tested per ASTM E1052-20 or EN 14476:2013+A2:2019 on SARS-CoV-2 in suspension studies with a 5% FBS organic load					
Antiseptic liquid [†]	4.7% w/v	0.094% w/v PCMX (tested at 1:50 of supplied)	21	5	≥ 4.7
Hand sanitizer gel [†]	61% w/w	49% w/w ethanol (tested at 1:1.25 of supplied)	21	1	≥ 4.2
Liquid hand wash [†]	0.10% w/w	0.025% w/w salicylic acid (tested at 1:4 of supplied)	37	1	≥ 3.1
Bar soap [‡]	0.11% w/w	0.018% w/w PCMX (tested at 1:6.25 of supplied)	38	1	≥ 3.0
Surface cleanser [‡]	0.096% w/w	0.077% w/w QAC [§] (tested at 1:1.25 of supplied)	21	5	≥ 4.1
Tested per ASTM E1053-20 on SARS-CoV-2 dried on a glass surface with a 5% FBS organic load					
Disinfectant wipes [¶]	0.19% w/w	0.19% w/w QAC [¶] (tested as supplied)	21	2	$\geq 3.5, \geq 3.5, \geq 3.5$
Disinfectant spray [¶]	50% w/w ethanol	50% w/w ethanol 0.083% w/w QAC [#] (tested as supplied)	21	2	$\geq 4.6, \geq 4.7, \geq 4.5$
	0.083% w/w QAC				

FBS, fetal bovine serum; PCMX, para-chloro-meta-xyleneol; QAC, quaternary ammonium compound; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 (isolate USA-WA1/2020, obtained from CDC through BRI Resources), w/v, weight to volume; w/w, weight to weight.

*Virucidal efficacy testing was conducted by Microbac Laboratories, Inc (Sterling, VA). The test cells were Vero E6, an African green monkey kidney cell obtained from American Type Culture Collection (ATCC CRL-1586). The growth medium was minimal essential medium supplemented with 5% FBS, L-glutamine, and antibiotics.

[†]Tested using EN 14476:2013+A2:2019 methodology.³

[‡]Tested using ASTM E1052-20 methodology.¹

[§]Alkyl dimethyl benzyl ammonium chloride (C12-16).

[¶]Where multiple values are displayed, this reflects the testing of multiple independent lots of the formulated microbicidal actives.

[¶]Alkyl (50% C14, 40% C12, 10% C16) dimethyl benzyl ammonium chloride.

[#]Alkyl (50% C14, 40% C12, 10% C16) dimethyl benzyl ammonium saccharinate.

relevant global standardized (ASTM International, EN) methodologies, for inactivating SARS-CoV-2. Products formulated with the microbicidal actives studied here should be useful for healthcare workers, researchers, and the public at large as critical interventions for infection prevention and control of SARS-CoV-2 and the ongoing COVID-19 pandemic.

References

1. ASTM International. ASTM E1052-20. Standard practice to assess the activity of microbicides against viruses in suspension. 2020; Available at: <https://www.astm.org/Standards/E1052.htm>. Accessed May 7, 2020.
2. ASTM International. ASTM E1053-20. Standard practice to assess virucidal activity of chemicals intended for disinfection of inanimate, nonporous environmental surfaces. 2020; Available at: <https://www.astm.org/Standards/E1053.htm>. Accessed May 7, 2020.
3. British Standards Institute. BS EN 14476:2013+A2:2019. Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements (Phase 2/Step 1). 2019; Available at: https://infostore.saiglobal.com/en-us/Standards/BS-EN-14476-2013-A2-2019-238423_SAIG_BSI_BSI_2753744/. Accessed May 7, 2020.
4. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. 2020; Available at: <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>. Accessed May 7, 2020.
5. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. *Lancet Microbe*. 2020;1:e10.
6. Ijaz MK, Zargar B, Wright KE, Rubino JR, Sattar SA. Generic aspects of the airborne spread of human pathogens indoor and emerging air decontamination technologies. *Am J Inf Control*. 2016;44(9 Suppl):S95–S101.
7. Ijaz MK, Rubino JR. Should test methods for disinfectants use vertebrate virus dried on carriers to advance virucidal claims? *Inf Control Hosp Epidemiol*. 2008;29:192–194.
8. Ijaz MK, Sattar SA, Rubino JR, Nims RW, Gerba CP. Combating SARS-CoV-2: leveraging microbicidal experiences with other emerging/re-emerging viruses. [e-pub ahead of print]. *OSF Preprints*. 2020. <https://doi.org/10.31219/osf.io/wjzsq>. Accessed June 9, 2020.

9. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. *J Hosp Inf*. 2020;104:246–251.

Conflicts of interest: None to report.

M. Khalid Ijaz, DVM, MSc(Honors), PhD, FRSPH*
 Kelly Whitehead, BS
 Vanita Srinivasan, MS
 Julie McKinney, PhD
 Joseph R. Rubino, BA, MA
 Mark Ripley, PhD
 Chris Jones, PhD

*Global Research & Development for Lysol and Dettol,
 Reckitt Benckiser LLC, Montvale, NJ, USA*

Raymond W. Nims, PhD
*RMC Pharmaceutical Solutions, Inc., Longmont,
 CO, USA*

Bruce Charlesworth, MD
*Global Medical Science, Reckitt Benckiser Health, Hull,
 United Kingdom*

- * Address correspondence to M. Khalid Ijaz, DVM, MSc(Honors), PhD, FRSPH, Global Research & Development for Lysol and Dettol, Reckitt Benckiser LLC, One Philips Parkway, Montvale, NJ 07645
E-mail address: Khalid.Ijaz@rb.com (M.K. Ijaz).

<https://doi.org/10.1016/j.ajic.2020.05.015>